期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 55, 期 22, 页码 9831-9837出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm3010515
关键词
-
资金
- Canadian Institutes for Health Research
- Canada Foundation for Innovation
- Genome Canada
- Pfizer
- GlaxoSmithKline
- Eli Lilly
- Novartis Research Foundation
- Abbott
- Ontario Ministry of Research and Innovation
- Wellcome Trust
The posttranslational modification of chromatin through acetylation at selected histone lysine residues is governed by histone acetyltransferases (HATs) and histone deacetylases (HDACs). The Significance of this subset of the epigenetic code, is interrogated and interpreted by an acetyllysine-Specific protein-protein interaction with bromodomain reader modules. Selective inhibition of the brome and extra C-terminal domain (BET) family of bromodomains. with a., small molecule is feasible, and this may represent an opportunity for disease intervention through the recently disclosed antiproliferative and anti inflammatory properties of such inhibitors Herein, we describe the discovery and structure activity relationship (SAR) of a novel; small molecule chemical probe for BET family inhibition that was identified through the application of structure based fragment,assessment and optimization techniques This has yielded a potent, selective compound with cell based activity (PFI-1) that may further add to the understanding of BET family function within the bromodomains.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据